BMS Downsizes In China Amid Slow Sales, Regulatory Uncertainty
This article was originally published in PharmAsia News
Executive Summary
BMS is slashing staff and operations in China to focus on selected areas in a harsh post-GSK affair business environment, while regulatory uncertainty underscored by China’s review of multi-regional clinical trials may be hurting the company even more, says an industry analyst.